AndreyPopovVertex's Investment in Innovation and Rare Disease Leadership Since my last look in December, Vertex's (NASDAQ:VRTX) stock performance has mirrored SPY, up 18%. My focus back then followed Vertex's VX-548 Phase 2 data in diabetic peripheral neuropathy (DPN), in which the oral selective inhibitor of the NaV1.8 sodium channel was on par with the popular and blockbuster neuropathy drug, Lyrica. The company's potential in DPN, among other prospects, including their existing fortress within the cy ...